{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T21:03:14Z","timestamp":1780520594362,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00277-022-04888-7","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T13:21:27Z","timestamp":1658150487000},"page":"1915-1924","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart review"],"prefix":"10.1007","volume":"101","author":[{"given":"Adam","family":"Cuker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lincy","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Carlyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Haenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Viana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"issue":"23","key":"4888_CR1","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, K\u00fchne T, Kuter DJ, Lim W, McCrae KR, Pruitt B, Shimanek H, Vesely SK (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3(23):3829\u20133866. https:\/\/doi.org\/10.1182\/bloodadvances.2019000966","journal-title":"Blood Adv"},{"issue":"11","key":"4888_CR2","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1001\/archinte.160.11.1630","volume":"160","author":"YC Cohen","year":"2000","unstructured":"Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B (2000) The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 160(11):1630\u20131638. https:\/\/doi.org\/10.1001\/archinte.160.11.1630","journal-title":"Arch Intern Med"},{"issue":"11","key":"4888_CR3","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, K\u00fchne T, Ruggeri M, George JN (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386\u20132393. https:\/\/doi.org\/10.1182\/blood-2008-07-162503","journal-title":"Blood"},{"issue":"2","key":"4888_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/ajh.20992","volume":"83","author":"R McMillan","year":"2008","unstructured":"McMillan R, Bussel JB, George JN, Lalla D, Nichol JL (2008) Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 83(2):150\u2013154. https:\/\/doi.org\/10.1002\/ajh.20992","journal-title":"Am J Hematol"},{"issue":"5","key":"4888_CR5","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1600-0609.2011.01587.x","volume":"86","author":"JL Newton","year":"2011","unstructured":"Newton JL, Reese JA, Watson SI, Vesely SK, Bolton-Maggs PH, George JN, Terrell DR (2011) Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol 86(5):420\u2013429. https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01587.x","journal-title":"Eur J Haematol"},{"issue":"26","key":"4888_CR6","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1182\/blood-2009-01-129155","volume":"113","author":"DB Cines","year":"2009","unstructured":"Cines DB, Bussel JB, Liebman HA, Luning Prak ET (2009) The ITP syndrome: pathogenic and clinical diversity. Blood 113(26):6511\u20136521. https:\/\/doi.org\/10.1182\/blood-2009-01-129155","journal-title":"Blood"},{"issue":"3","key":"4888_CR7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ajh.21616","volume":"85","author":"DR Terrell","year":"2010","unstructured":"Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN (2010) The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 85(3):174\u2013180. https:\/\/doi.org\/10.1002\/ajh.21616","journal-title":"Am J Hematol"},{"issue":"5","key":"4888_CR8","doi-asserted-by":"publisher","first-page":"A342","DOI":"10.1016\/j.autrev.2009.11.020","volume":"9","author":"S Deane","year":"2010","unstructured":"Deane S, Teuber SS, Gershwin ME (2010) The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev 9(5):A342-349. https:\/\/doi.org\/10.1016\/j.autrev.2009.11.020","journal-title":"Autoimmun Rev"},{"issue":"6","key":"4888_CR9","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.hoc.2009.08.004","volume":"23","author":"PF Fogarty","year":"2009","unstructured":"Fogarty PF (2009) Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation. Hematol Oncol Clin North Am 23(6):1213\u20131221. https:\/\/doi.org\/10.1016\/j.hoc.2009.08.004","journal-title":"Hematol Oncol Clin North Am"},{"key":"4888_CR10","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"D Provan","year":"2019","unstructured":"Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, Gonz\u00e1lez-L\u00f3pez TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ (2019) Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3:3780\u20133817. https:\/\/doi.org\/10.1182\/bloodadvances.2019000812","journal-title":"Blood Adv"},{"issue":"9763","key":"4888_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","volume":"377","author":"G Cheng","year":"2011","unstructured":"Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB (2011) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 377(9763):393\u2013402. https:\/\/doi.org\/10.1016\/S0140-6736(10)60959-2","journal-title":"Lancet"},{"key":"4888_CR12","doi-asserted-by":"publisher","unstructured":"Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, ArningM (2009) Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double\u2010blind, placebo-controlled trial. Lancet 373(9664):641\u2010648. https:\/\/doi.org\/10.1016\/S0140-6736(09)60402-5","DOI":"10.1016\/S0140-6736(09)60402-5"},{"issue":"1","key":"4888_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/bjh.14380","volume":"176","author":"R Yang","year":"2017","unstructured":"Yang R, Li J, Jin J, Huang M, Yu Z, Xu X, Zhang X, Hou M (2017) Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Br J Haematol 176(1):101\u2013110. https:\/\/doi.org\/10.1111\/bjh.14380","journal-title":"Br J Haematol"},{"issue":"9610","key":"4888_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","volume":"371","author":"DJ Kuter","year":"2008","unstructured":"Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefr\u00e8re F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371(9610):395\u2013403. https:\/\/doi.org\/10.1016\/S0140-6736(08)60203-2","journal-title":"Lancet"},{"issue":"10039","key":"4888_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","volume":"388","author":"MD Tarantino","year":"2016","unstructured":"Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M (2016) Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388(10039):45\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(16)00279-8","journal-title":"Lancet"},{"issue":"1","key":"4888_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12185-011-0886-8","volume":"94","author":"Y Shirasugi","year":"2011","unstructured":"Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R (2011) Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Int J Hematol 94(1):71\u201380. https:\/\/doi.org\/10.1007\/s12185-011-0886-8","journal-title":"Int J Hematol"},{"issue":"2","key":"4888_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/bjh.13827","volume":"172","author":"A Newland","year":"2016","unstructured":"Newland A, Godeau B, Priego V (2016) Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol 172(2):262\u2013273. https:\/\/doi.org\/10.1111\/bjh.13827","journal-title":"Br J Haematol"},{"key":"4888_CR18","doi-asserted-by":"publisher","unstructured":"Al-Samkari H, Nagalla S (2021) Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. Platelets :1\u20138. https:\/\/doi.org\/10.1080\/09537104.2021.1881952","DOI":"10.1080\/09537104.2021.1881952"},{"issue":"10","key":"4888_CR19","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","volume":"113","author":"JB Bussel","year":"2009","unstructured":"Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL (2009) Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113(10):2161\u20132171. https:\/\/doi.org\/10.1182\/blood-2008-04-150078","journal-title":"Blood"},{"issue":"23","key":"4888_CR20","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","volume":"130","author":"RSM Wong","year":"2017","unstructured":"Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB (2017) Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 130(23):2527\u20132536. https:\/\/doi.org\/10.1182\/blood-2017-04-748707","journal-title":"Blood"},{"issue":"3","key":"4888_CR21","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1002\/ajh.23900","volume":"90","author":"TJ Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez TJ, Pascual C, Alvarez-Roman MT (2015) Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 90(3):E40-43. https:\/\/doi.org\/10.1002\/ajh.23900","journal-title":"Am J Hematol"},{"issue":"1","key":"4888_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12185-015-1793-1","volume":"102","author":"L \u010cervinek","year":"2015","unstructured":"\u010cervinek L, Mayer J, Doubek M (2015) Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. Int J Hematol 102(1):7\u201311. https:\/\/doi.org\/10.1007\/s12185-015-1793-1","journal-title":"Int J Hematol"},{"key":"4888_CR23","doi-asserted-by":"publisher","unstructured":"Lucchini E, Palandri F, Volpetti S, Vianelli N, Auteri G, Rossi E, Patriarca A, Carli G, Barcellini W, Celli M, Consoli U, Valeri F, Santoro C, Crea E, Vignetti M, Paoloni F, Gigliotti CL, Boggio E, Dianzani U, Giardini I, Carpenedo M, Rodeghiero F, Fanin R, Zaja F; for Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) (2021) Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. Br J Haematol 192(2):386\u2013396. https:\/\/doi.org\/10.1111\/bjh.17334","DOI":"10.1111\/bjh.17334"},{"issue":"6","key":"4888_CR24","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676\u2013682. https:\/\/doi.org\/10.1093\/aje\/kwq433","journal-title":"Am J Epidemiol"},{"issue":"4","key":"4888_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000510676","volume":"144","author":"N Cooper","year":"2021","unstructured":"Cooper N, Hill Q, Grainger J, Westwood JP, Bradbury C, Provan D, Thachil J, Ramscar N, Roy A (2021) Real-world tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: Results from a modified Delphi Panel. Acta Haematol 144(4):418\u2013426. https:\/\/doi.org\/10.1159\/000510676","journal-title":"Acta Haematol"},{"issue":"11","key":"4888_CR26","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1111\/trf.12139","volume":"53","author":"B Ghadaki","year":"2013","unstructured":"Ghadaki B, Nazi I, Kelton JG, Arnold DM (2013) Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 53(11):2807\u20132812. https:\/\/doi.org\/10.1111\/trf.12139","journal-title":"Transfusion"},{"issue":"6","key":"4888_CR27","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bjh.12888","volume":"165","author":"M Mah\u00e9vas","year":"2014","unstructured":"Mah\u00e9vas M, Fain O, Ebbo M, Roudot-Thoraval F, Limal N, Khellaf M, Schleinitz N, Bierling P, Languille L, Godeau B, Michel M (2014) The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 165(6):865\u2013869. https:\/\/doi.org\/10.1111\/bjh.12888","journal-title":"Br J Haematol."},{"issue":"2","key":"4888_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12185-020-02893-y","volume":"112","author":"M Iino","year":"2020","unstructured":"Iino M, Sakamoto Y, Sato T (2020) Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice. Intl J Hematol 112(2):159\u2013168. https:\/\/doi.org\/10.1007\/s12185-020-02893-y","journal-title":"Intl J Hematol"},{"key":"4888_CR29","doi-asserted-by":"publisher","unstructured":"Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefr\u00e8re F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mah\u00e9vas M, Languille L, Bierling P, Godeau B (2011) Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 118(16):4338-4345. https:\/\/doi.org\/10.1182\/blood-2011-03-340166","DOI":"10.1182\/blood-2011-03-340166"},{"issue":"7","key":"4888_CR30","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/rth2.12423","volume":"4","author":"LS Lal","year":"2020","unstructured":"Lal LS, Said Q, Andrade K, Cuker A (2020) Second-line treatments and outcomes for immune thrombocytopenia: a retrospective study with electronic health records. Res Pract Thromb Haemost 4(7):1131\u20131140. https:\/\/doi.org\/10.1002\/rth2.12423","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04888-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04888-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04888-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T05:24:21Z","timestamp":1660368261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04888-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["4888"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04888-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]},"assertion":[{"value":"7 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Adam Cuker served as a consultant for Synergy, has received authorship royalties from UpToDate, and his institution has received research support on his behalf from Alexion, Bayer, Novartis, Novo Nordisk, Pfizer, Sanofi, Spark, and Takeda. Lincy Lal was an employee of Optum, which was paid by Novartis to conduct this study, at the time of the study. Anuja Roy was an employee of Novartis at the time of the study. Caitlin Elliott was an employee of Optum, which was paid by Novartis to conduct this study. Maureen Carlyle is an employee of Optum, which was paid by Novartis to conduct this study. Carolyn Martin is an employee of Optum, which was paid by Novartis to conduct this study. Jens Haenig is a Novartis AG employee and holds shares. Ricardo Viana is a Novartis AG employee and holds shares.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}